a man wearing sunglasses and a leather jacket is talking about scientists . ALT: a man wearing sunglasses and a leather jacket is talking about scientists .

time.com/6266923/ai-e...

This is very sad for the US but incredibly smart by Norway

#YorkshireDales #waterfall

Summit of #Ingleborough peak in #YorkshireDales

#Ingleborough Peak in #YorkshireDales

Elections have consequences

I wish things were boring again. Uneventful. Unremarkable. Dull even. Nothing happening that's noteworthy.

Interesting times are vastly overrated.

Former FDA officials call HHS plan for agency ‘nonsensical,’ unworkable The Department of Health and Human Services has developed a plan for reorganizing FDA. Former senior FDA officials told BioCentury the proposal is infeasib...

Must read: How reductions in force and a planned reorganization of #FDA could dramatically reduce the agency's ability to perform essential functions -- from my colleague @steveusdin.bsky.social
www.biocentury.com/article/655559

Buckle up.

From our 2025 #BioCentury financial markets preview: www.biocentury.com/article/654637

There are 33m companies in the USA. Only 21k employe 500 or more. And they only make up 23% of workers.

Trump and Elon are ignoring the more than 32m entrepreneurs that can't afford to build a new factory or pay tariffs or absorb cancelled contracts.

a close up of a man 's face with the words `` and like that ... he 's gone '' written on it . ALT: a close up of a man 's face with the words `` and like that ... he 's gone '' written on it .

"And like that, the market is gone" #tariffs

Trump Won’t Rule Out Seeking Third Term, Says There Are Ways President Donald Trump said he wouldn’t rule out seeking a third term in the White House, telling NBC News in a phone interview on Sunday that “there are methods” that would allow him to do so.

The 22nd Amendment prohibits US presidents from serving more than two terms

Very interesting study. What is your DHRPS? www.ahajournals.org/doi/epdf/10....

Up is down, blue is red, night is day, south is north.

Oral Ozempic reduced major adverse cardiovascular events in a large randomized trial of 9,650 participants with T2 diabetes and high-risk
@nejm.org #ACC25
www.nejm.org/doi/full/10....

Cuts at #FDA put the agency at risk of missing PDUFA goals - from my colleague @steveusdin.bsky.social : www.biocentury.com/article/655466

A Pentagon-wide email recently went out warning about Signal's vulnerability A Pentagon-wide advisory that went out one week ago warns against using the Signal, the messaging app, even for unclassified information.

A Pentagon-wide advisory that went out one week ago warns against using the Signal, the messaging app, even for unclassified information.

Thanks to global immunisation efforts, an estimated 154 million lives have been saved over the past 50 years 🌎 🤝

That’s equivalent to 6 lives every minute.

#CelebrateVaccines

My latest on the #Zealand and #Roche deal for amylin agonist pretrelintide: www.biocentury.com/article/655330

Could amylin outshine GLP-1 in obesity? Incretin-based therapies have dominated the weight-loss Olympics, with companies chasing higher percentage losses like athletes chasing record-breaking sco...

With the #Roche and #Zealand deal for up to $5.3B for #amylin agonist #petrelintide in #obesity, re-upping my story from last week on the promise of amylin in #obesity: www.biocentury.com/article/655255

Could amylin outshine GLP-1 in obesity? Incretin-based therapies have dominated the weight-loss Olympics, with companies chasing higher percentage losses like athletes chasing record-breaking sco...

With the #Roche and #Zealand deal for up to $5.3B for #amylin agonist #petrelintide in #obesity, re-upping my story from last week on the promise of amylin in #obesity: www.biocentury.com/article/655255

Nightmarish stuff in here.

👀

#bluesky Saturday⛱️

@minakimes.bsky.social PARADISE 🤯

Could amylin outshine GLP-1 in obesity? Incretin-based therapies have dominated the weight-loss Olympics, with companies chasing higher percentage losses like athletes chasing record-breaking sco...

Could amylin outshine GLP-1 in obesity? 🔬

Will amylin reshape the obesity treatment landscape? 📊

Sure feels that way.

Novo, Lilly, and AZ are already in the game, and AbbVie just dropped $350M on an amylin asset.

📖 Access to the full report here: www.biocentury.com/article/6552...

Holy shit!! Trump just slipped on live TV that he lost the 2020 presidential election.

Trump would HATE it if this goes viral:

#GLP1 sales continue to boom thanks to #obesity market expansion #biosky #medsky www.biocentury.com/article/655202